MCID: DYS011
MIFTS: 28

Dyskinesia of Esophagus malady

Categories: Gastrointestinal diseases

Aliases & Classifications for Dyskinesia of Esophagus

Aliases & Descriptions for Dyskinesia of Esophagus:

Name: Dyskinesia of Esophagus 12 14
Esophageal Motility Disorders 52 42 69
Esophageal Motility Disorder 12
Oesophageal Motor Disorder 12
Dyskinesia of Oesophagus 12
Oesophageal Dysmotility 12
Esophageal Dysmotility 12
Esophageal Spasm 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9192
ICD10 33 K22.4
ICD9CM 35 530.5
MeSH 42 D015154
UMLS 69 C0014858

Summaries for Dyskinesia of Esophagus

MalaCards based summary : Dyskinesia of Esophagus, also known as esophageal motility disorders, is related to crest syndrome and esophagitis, and has symptoms including spasm An important gene associated with Dyskinesia of Esophagus is ATP4A (ATPase H+/K+ Transporting Alpha Subunit). The drugs Dopamine and Pantoprazole have been mentioned in the context of this disorder. Related phenotype is Increased shRNA abundance (Z-score > 2).

Related Diseases for Dyskinesia of Esophagus

Graphical network of the top 20 diseases related to Dyskinesia of Esophagus:



Diseases related to Dyskinesia of Esophagus

Symptoms & Phenotypes for Dyskinesia of Esophagus

UMLS symptoms related to Dyskinesia of Esophagus:


spasm

GenomeRNAi Phenotypes related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.6 AGPAT2 SLCO2A1 UBTF
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.6 AGPAT2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.6 SLCO2A1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.6 UBTF
5 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.6 UBTF
6 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.6 UBTF
7 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.6 SLCO2A1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.6 SLCO2A1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.6 UBTF
10 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.6 UBTF
11 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.6 AGPAT2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.6 AGPAT2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.6 AGPAT2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.6 UBTF
15 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.6 SLCO2A1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.6 AGPAT2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.6 UBTF

Drugs & Therapeutics for Dyskinesia of Esophagus

Drugs for Dyskinesia of Esophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 287)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 1 51-61-6, 62-31-7 681
2
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1 102625-70-7 4679
3
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
4
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 103577-45-3 3883
5
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
6
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 161796-78-7, 119141-88-7 4594 9579578
7
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3 57808-66-9 3151
8
Menthol Approved Phase 4,Phase 1,Phase 2 2216-51-5 16666
9
Ethanol Approved Phase 4 64-17-5 702
10
Cimetidine Approved Phase 4 51481-61-9 2756
11
Metoclopramide Approved, Investigational Phase 4,Phase 3 364-62-5 4168
12
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3 75614-87-8, 51-45-6 774
13
Ranitidine Approved Phase 4,Phase 3,Phase 2 66357-59-3, 66357-35-5 3001055
14
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
15
Famotidine Approved Phase 4,Phase 2,Phase 3 76824-35-6 3325
16
Olanzapine Approved, Investigational Phase 4,Phase 1 132539-06-1 4585
17
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078 2978
18
Remifentanil Approved Phase 4 132875-61-7 60815
19
Nortriptyline Approved Phase 4,Phase 2,Phase 3 72-69-5 4543
20
Nizatidine Approved Phase 4,Phase 3 76963-41-2 3033637
21
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 1 21645-51-2
22
Magnesium Hydroxide Approved Phase 4,Phase 1 1309-42-8
23 Magnesium trisilicate Approved Phase 4,Phase 3,Phase 1 14987-04-3
24
Citalopram Approved Phase 4 59729-33-8 2771
25 Trimebutine Approved Phase 4 39133-31-8
26
Polidocanol Approved Phase 4 9002-92-0
27
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
28
Clozapine Approved Phase 4 5786-21-0 2818
29
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
30
Ziprasidone Approved Phase 4 146939-27-7 60854
31
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
32
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
33
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
34
Clarithromycin Approved Phase 4 81103-11-9 84029
35
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
36
Methylene blue Investigational Phase 4 61-73-4
37
Maleic acid Experimental Phase 4 110-16-7 444266
38 mometasone furoate Phase 4,Phase 2 83919-23-7
39
Dexlansoprazole Phase 4,Phase 3,Phase 2,Phase 1 138530-94-6, 103577-45-3 9578005
40
Proton pump inhibitors Phase 4,Phase 3,Phase 2,Phase 1
41 Analgesics Phase 4,Phase 1
42 Cholinergic Agents Phase 4,Phase 2,Phase 1
43 Adrenergic Agents Phase 4,Phase 3,Phase 2
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Coagulants Phase 4,Phase 3
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47
Alginic acid Phase 4,Phase 3,Phase 1 9005-32-7
48 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3
49 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
50 Hemostatics Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 730)
id Name Status NCT ID Phase
1 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
2 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
3 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4
4 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
5 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4
6 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4
7 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4
8 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4
9 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4
10 The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain Completed NCT01598207 Phase 4
11 PPI Sequencing Study Completed NCT00384592 Phase 4
12 On Demand Treatment of Reflux Disease Completed NCT00184522 Phase 4
13 Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease. Completed NCT01601379 Phase 4
14 A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg Completed NCT00464308 Phase 4
15 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4
16 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4
17 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4
18 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4
19 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4
20 Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) Completed NCT00261339 Phase 4
21 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4
22 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4
23 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Dise Completed NCT00629564 Phase 4
24 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4
25 Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv Completed NCT00626262 Phase 4
26 Esomeprazole in PPI Failures - IMPROVE Completed NCT00272701 Phase 4
27 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4
28 Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B Completed NCT03128736 Phase 4
29 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4
30 Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously Completed NCT00635414 Phase 4
31 CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing Completed NCT00354757 Phase 4
32 Validation of RDQ Questionnaire Completed NCT00291746 Phase 4
33 Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342) Completed NCT00325676 Phase 4
34 The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity Completed NCT02958046 Phase 4
35 Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD Completed NCT00304421 Phase 4
36 Symptom Adapted Therapy in GERD Patients Completed NCT00343161 Phase 4
37 Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI) Completed NCT00251732 Phase 4
38 Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD Completed NCT00410592 Phase 4
39 Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response Completed NCT00392002 Phase 4
40 Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea Completed NCT01018160 Phase 4
41 Esomeprazole for Treatment of GERD in Pediatric Patients Completed NCT00228527 Phase 4
42 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4
43 Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Completed NCT00373997 Phase 4
44 A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD) Completed NCT00216489 Phase 4
45 Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Completed NCT00287391 Phase 4
46 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed NCT00444145 Phase 4
47 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disea Completed NCT00628342 Phase 4
48 Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD) Completed NCT00637845 Phase 4
49 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
50 Evaluation of Patients With Non-cardiac Chest Pain Completed NCT00476398 Phase 4

Search NIH Clinical Center for Dyskinesia of Esophagus

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: esophageal motility disorders

Genetic Tests for Dyskinesia of Esophagus

Anatomical Context for Dyskinesia of Esophagus

Publications for Dyskinesia of Esophagus

Variations for Dyskinesia of Esophagus

Expression for Dyskinesia of Esophagus

Search GEO for disease gene expression data for Dyskinesia of Esophagus.

Pathways for Dyskinesia of Esophagus

GO Terms for Dyskinesia of Esophagus

Cellular components related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 fibrillar center GO:0001650 8.62 TOP1 UBTF

Sources for Dyskinesia of Esophagus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....